8-K: Genprex Announces Biomarker Data for Lung Cancer Therapy

Genprex, Inc. reported positive clinical data from studies of predictive biomarkers for its lead drug candidate, Reqorsa Gene Therapy, in lung cancer patients at the 2026 ASCO Annual Meeting.

Summary

• Genprex, Inc. announced that an abstract detailing positive clinical data for its lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
• The data, from patients in the company's Acclaim clinical trials, supports earlier preclinical findings that Non-Small Cell Lung Cancer (NSCLC) patients with high Trop-2 levels and low PTEN levels experience prolonged Progression Free Survival (PFS) when treated with REQORSA.
• This suggests that Trop-2 and PTEN protein expression can serve as predictive biomarkers for treatment efficacy.
• In NSCLC patients, Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05), and PTEN H-scores below 100 correlated with prolonged PFS (p=0.03).
• In Small Cell Lung Cancer (SCLC) patients, Trop-2 H-scores were universally low and PTEN H-scores did not correlate with prolonged PFS.
• Further analysis indicated that NSCLCs with 3+ Trop-2 staining had a strong relationship with PFS (p=0.053), and high (3+) Trop-2 expression will be investigated further as a potential biomarker.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the identification of predictive biomarkers that correlate with improved patient outcomes, supporting the potential efficacy of Reqorsa Gene Therapy.

Positives

• Positive clinical data published at the 2026 ASCO Annual Meeting for Reqorsa Gene Therapy.
• Identified predictive biomarkers (high Trop-2, low PTEN) correlating with prolonged Progression Free Survival (PFS) in NSCLC patients.
• Trop-2 H-scores above 100 correlated with prolonged PFS in NSCLC patients (p=0.05).
• PTEN H-scores below 100 correlated with prolonged PFS in NSCLC patients (p=0.03).
• High (3+) Trop-2 expression shows a strong relationship with PFS in NSCLC (p=0.053) and will be investigated further.
• Biomarkers may enable targeted patient selection and precision medicine approaches.

Negatives

• Biomarker correlations for prolonged PFS were not observed in Small Cell Lung Cancer (SCLC) patients.
• PTEN H-scores in SCLC patients did not correlate with prolonged PFS (p=0.53).
• The relationship between 3+ PTEN staining and PFS in NSCLC showed a trend for a negative relationship that was not statistically significant (p=0.309).

Risks

• Actual results may differ materially from forward-looking statements due to significant risks and uncertainty.
• Potential risks include challenges in clinical development, manufacturing, and commercialization of product candidates.
• Uncertainty regarding the timing and success of clinical trials and regulatory approvals.
• The ability to maintain compliance with Nasdaq Capital Market listing requirements and continue as a going concern.
• The need to obtain capital to meet long-term liquidity needs on acceptable terms, or at all.
• Reliance on third-party vendors, suppliers, and manufacturers for product candidate manufacturing.

Future Outlook

The identified biomarkers may predict patient response, enable targeted patient selection, and allow for precision medicine. High (3+) Trop-2 expression will be investigated further as a potential biomarker for REQORSA. Forward-looking statements address Genprex's ability to advance clinical development, manufacturing, and commercialization, the timing and success of clinical trials and regulatory approvals, and future growth and financial status, including liquidity needs and Nasdaq compliance.

Management Comments

• The identified biomarkers may predict patient response, enable targeted patient selection and allow for precision medicine.
• High (3+) Trop-2 expression will be investigated further as a potential biomarker for REQORSA.

Industry Context

StockSavvy.ai notes that the publication of biomarker data at ASCO is a significant event in the oncology space, highlighting the industry's move towards personalized medicine and targeted therapies. Genprex's findings on Trop-2 and PTEN could position Reqorsa Gene Therapy favorably if validated in larger trials, especially in the competitive NSCLC market.

Stakeholder Impact

• Shareholders may see increased confidence in the company's lead drug candidate due to positive clinical data and biomarker identification.
• Patients with NSCLC may benefit from more targeted treatment options if Reqorsa Gene Therapy proves effective based on these biomarkers.
• The medical community will note the potential for Trop-2 and PTEN as predictive biomarkers in lung cancer treatment.

Next Steps

• Further investigation of high (3+) Trop-2 expression as a potential biomarker for REQORSA.
• Advancing the clinical development, manufacturing, and commercialization of product candidates.
• Seeking regulatory approvals for product candidates.
• Addressing future growth and financial status, including liquidity needs and Nasdaq compliance.

Key Dates

Recommendation

The filing presents positive biomarker data for Reqorsa Gene Therapy in NSCLC, which is encouraging. However, the data is from a small number of patients and specific to certain trial arms. Further validation and progression through clinical trials are necessary before a stronger recommendation can be made. The company's ongoing financial stability and Nasdaq compliance also remain factors to monitor.

Keywords

Genprex, Reqorsa Gene Therapy, quaratusugene ozeplasmid, lung cancer, NSCLC, SCLC, biomarkers, Trop-2, PTEN, ASCO, clinical trials, PFS